Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 3Recruiting 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

pembrolizumab 73Carboplatin 60Cyclophosphamide 59Nivolumab 52Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 36Rituximab 32Capecitabine 32Bevacizumab 29Docetaxel 28fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Ipilimumab 22Fluorouracil 22Azacitidine 22Temozolomide 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Hematopoietic Stem Cell Transplantation × Clear all
NCT01350258 2025-05-31

Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps

Thomas Jefferson University

Phase 1/2 Terminated
8 enrolled 8 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡